Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery

Not Applicable

Recruiting

• Conditions: Obesity

• Registration Number: NCT06278285
• Lead Sponsor: Centre Hospitalier Universitaire de Nice

Brief Summary

Normalizing weight gain and preventing the redistribution of body fat is a major health issue, and could help prevent the onset of various symptoms of metabolic syndrome. Above all, it is important to understand the mechanisms by which these different treatments affect adipose tissue. To this end, the investigators will first study the impact of GLP-1 analogues on adipose tissue. The main objective is to show that subjects treated with a GLP-1 agonist have a significant change in their oxytocin levels compared with subjects not treated with a GLP-1 agonist.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-02-09
• Study First Submitted QC: 2024-02-22
• Study First Posted: 2024-02-26
• Study Start: 2024-03-06
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-17
• Last Update Posted: 2025-03-18
• Primary Completion: 2026-09-06
• Study Completion: 2027-03-06

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Patient over 18 years of age.
• Patient able to read and understand the information/consent leaflet.
• Patient with BMI > 35 with at least one comorbidity. Or BMI > 40
• Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM.
• Membership of a social security scheme
• Patient's signed informed consent
• For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months.
• For non-GLP-1 analogue group: never taken GLP-1 analogues.

Exclusion Criteria

• Pregnant or breast-feeding women.
• Vulnerable patients (under guardianship)
• Patients deprived of liberty

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Rate of oxytocin	one time (before surgery)	show that subjects treated with a GLP-1 agonist have a significant change in oxytocin levels compared with subjects not treated with a GLP-1 agonist.

Secondary Outcome Measures

Name	Time	Method
Fibrosis rate	At surgery	compare adipose tissue caracteristics between patients treated by analog GLP1 and not treated by analog GLP1

Trial Locations

Locations (1)

CHU de Nice - Hôpital de l'Archet; 🇫🇷 Nice, Alpes-maritimes, France